✦ LIBER ✦

Cost-Effectiveness And Cost-Utility Analysis Of Sunitinib Versus Sorafenib And Bevacizumab + Interferon-Alfa As First-Line Treatment For Metastatic Renal Cell Carcinoma In Ecuador

✍ Scribed by Torres Toala, F.G.; Albuja Riofrio, M.F.; Mould, J.F.; Estévez, C.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN26 COST-EFFECTIVENESS AND COST-UTILIT

✍ Salinas-Escudero, G; Contreras-Hernandez, I; Mould-Quevedo, J 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

PCN70 COST EFFECTIVENESS ANALYSIS OF SUN

✍ E Remák; H Vioix; R Sandin; U Harmenberg; A Ullén; P Sandström 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

PCN59 Cost-Effectiveness of Pazopanib Ve

✍ Pepe, C.; Paladini, L.; Sedlmayer, C.; Machado, M. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

PUK17 Cost-Mimimization Analysis of Pazo

✍ M. Sura; S. Goryaynov; M. Avxentyeva; V. Omelyanovsky 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

PCN62 Cost-Effectiveness Analysis of Fir

✍ Nuñez, S.M.; Godoy, J.I.; Cardona, A.F.; Otero, J.M.; Lujan, M.; Lopera, D.; Car 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Cost-Effectiveness of Pazopanib as First

✍ Pepe, C.; Sedlmayer, C.; Machado, M. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB